Oppenheimer analyst Jay Olson maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and adjusts the target price from $55 to $60.
According to TipRanks data, the analyst has a success rate of 39.0% and a total average return of 12.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
The initial Phase 1 data from RMC-9805 in patients with advanced pancreatic ductal adenocarcinoma presented at the EORTC-NCI-AACR Symposium bolstered the outlook for the ongoing second-line PDAC Phase 3 study of RMC-6036. The updated Phase 1/1b data that was shared last week has increased confidence in the potential success of the study.
Following recent clinical updates on '6236 and '9805 in PDAC, and an investor event, there is a positive outlook on the potential of '6236 in second line or later PDAC treatment, as the latest Phase 1 data indicated an enhanced median overall survival. Furthermore, initial data from the first-in-human trials of '9805 in PDAC has shown promising signs of clinical efficacy and an acceptable safety profile, exceeding initial expectations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奥本海默控股分析师Jay Olson维持$Revolution Medicines (RVMD.US)$买入评级，并将目标价从55美元上调至60美元。
根据TipRanks数据显示，该分析师近一年总胜率为39.0%，总平均回报率为12.9%。
此外，综合报道，$Revolution Medicines (RVMD.US)$近期主要分析师观点如下：
在 EORTC-NCI-AACR 研讨会上公布的 RMC-9805 针对晚期胰腺导管腺癌患者的初始 1 期数据增强了正在进行的 RMC-6036 二线 PDAC 3 期研究的前景。上周分享的最新10/10期数据增强了人们对该研究潜在成功的信心。
继最近PDAC中'6236和'9805的临床更新以及一次投资者活动之后，由于最新的1期数据显示总存活率中位数有所提高，人们对'6236在二线或以后的PDAC治疗中的潜力持乐观态度。此外，在PDAC中进行'9805的首次人体试验的初步数据显示出令人鼓舞的临床疗效迹象和可接受的安全性，超出了最初的预期。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
